Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
06:55pm, Thursday, 07'th Mar 2024
Astrazeneca (AZN) closed the most recent trading day at $66.19, moving +1.41% from the previous trading session.
Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows
02:00pm, Thursday, 07'th Mar 2024
AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease Contro
AstraZeneca to invest 650 million pounds in UK to boost 'pandemic preparedness'
10:01am, Wednesday, 06'th Mar 2024
AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on Wednesday as part of Finance Minis
AstraZeneca to invest £650mln in UK life sciences
08:29am, Wednesday, 06'th Mar 2024
Chancellor Jeremy Hunt also announced that British pharma giant AstraZeneca PLC (LSE:AZN) plans to invest £650 million in UK life sciences. Under levelling-up plans, AstraZeneca will develop a vacci
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
10:00am, Tuesday, 05'th Mar 2024
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
06:51pm, Friday, 01'st Mar 2024
In the closing of the recent trading day, Astrazeneca (AZN) stood at $64.60, denoting a +0.69% change from the preceding trading day.
Judge rejects AstraZeneca's challenge to Medicare drug price negotiations
02:02pm, Friday, 01'st Mar 2024
U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.
3 Inflation-Resilient Stocks to Weather the Economic Turbulence
10:10am, Wednesday, 28'th Feb 2024
Even after aggressive contractionary monetary policies by the federal reserve, inflation has remained relatively stubborn. Supply-chain issues and an increase in price of agricultural commodities are
FibroGen regains rights to anemia drug from AstraZeneca
04:18pm, Monday, 26'th Feb 2024
FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
10:06am, Friday, 23'rd Feb 2024
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Move Over Magnificent 7, Say Hello to the GRANOLAS
06:10am, Thursday, 22'nd Feb 2024
There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.
Positive lung cancer results show our strategy is working: AstraZeneca
12:00pm, Monday, 19'th Feb 2024
Greg Rossi, senior vice president of oncology in Europe and Canada at AstraZeneca, discusses the company's three announcements on lung cancer drugs and treatments.
AstraZeneca's stock surges on FTSE 100 on Tagrisso approval
11:09am, Monday, 19'th Feb 2024
AstraZeneca's (LON: AZN) stock surged on the FTSE 100 index following the announcement of the approval of its lung-cancer drug Tagrisso, in combination with chemotherapy. AstraZaneca's shares were up
AstraZeneca's new lung cancer drugs to boost sales - UBS
04:57am, Monday, 19'th Feb 2024
AstraZeneca PLC (LSE:AZN) is set to see a sales boost from new lung cancer treatments, according to UBS analysts, after the pharmaceuticals firm updated on two treatments on Monday. UBS anticipated pe
AstraZeneca rallies as results show Tagrisso slows lung cancer progression
03:37am, Monday, 19'th Feb 2024
AstraZeneca PLC (LSE:AZN) shares swung 4% higher on Monday after it emerged that blockbuster drug Tagrisso (osimertinib), with the addition of chemotherapy, has been approved in the US for the treat
